<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) are challenging to treat, given the advanced median age and comorbidities of the population </plain></SENT>
<SENT sid="1" pm="."><plain>For most patients, the standard therapy is supportive care, including broad-spectrum antibiotics, red blood cell/platelet transfusions, and growth factors </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="50131">Decitabine</z:chebi>, a hypomethylating agent that allows for the re-expression of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor genes, represents an exciting new treatment option for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients </plain></SENT>
<SENT sid="3" pm="."><plain>In phase 2 and 3 studies, <z:chebi fb="0" ids="50131">decitabine</z:chebi> has been associated with durable responses in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients and delayed time to <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) transformation or <z:hpo ids='HP_0011420'>death</z:hpo> compared with supportive care </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="0" ids="50131">Decitabine</z:chebi> has been shown to be well tolerated with a toxicity profile expected for this class of agent </plain></SENT>
<SENT sid="5" pm="."><plain>Recent studies also suggest that lower dose schedules of <z:chebi fb="0" ids="50131">decitabine</z:chebi> may result in additional improvements in response </plain></SENT>
<SENT sid="6" pm="."><plain>As more is learned about the mechanism of hypomethylating agents, new roles are emerging for <z:chebi fb="0" ids="50131">decitabine</z:chebi> in combination therapy for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and in other <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e> such as <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
</text></document>